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Background: To analyze our experience and to describe access and arch-related challenges when 
performing thoracic endovascular aortic repair (TEVAR) for penetrating aortic ulcers (PAUs).
Methods: This is a single-center, observational, cohort study. Between October 2003 and February 2019, 
48 patients with PAU were identified; 37 (77.1%) treated with TEVAR were retrospectively analyzed. 
Primary major outcomes were early (<30 days) and late survival, freedom from aortic-related mortality (ARM), 
and a composite endpoint of arch/vascular access-related complications.
Results: On admission, 17 (45.9%) patients were symptomatic with 4 (10.8%) presenting with rupture. In-
hospital mortality was 8.1% (n=3). We observed 10 (27.0%) arch/access-related complications. There were 
4 (10.8%) arch issues: 2 transient ischemic attacks and 2 retrograde acute type A dissections which required 
emergent open conversion for definitive repair. Access issues occurred in 6 (16.2%) patients: 3 (8.1%) required 
common iliac artery conduit, and 1 (2.7%) patient required iliac artery angioplasty to deliver the stent-graft. 
In addition, 2 (5.4%) patients developed access complications which required operative repair [femoral patch 
angioplasty (n=2), and femoral pseudoaneurysmectomy (n=1)]. Arch/access-related mortality rate was 5.4% (n=2) 
and median follow-up was 24 (range, 1–156; IQR, 3–52) months. Estimated survival was 87.1% (standard error: 
0.6; 95% CI: 71.2–84.9%) at 1 year, and 63.3% (SE: 0.9; 95% CI: 44.1–79%) at 4 years. Estimated freedom 
from reintervention was 88.9% (SE: 0.5; 95% CI: 74.8–95.6%) at 1 year, and 84.2% (SE: 0.7; 95% CI: 67.3–
93.2%) at 4 years. No arch/access-related issues developed during the follow-up period.
Conclusions: Our experience confirms that vascular access and aortic arch issues are still a challenging 
aspect of performing TEVAR for PAUs. Our cumulative 27% rate of access/arch issues is lower than 
previously reported due to both technological advancements and meticulous management of both access 
routes and arch anatomy.
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Introduction
The treatment of penetrating atherosclerotic ulcers 
(PAU) remains controversial. There is clinical overlap 
between PAU and aortic ulcer-like projections (ULP) 
that has been reported in several series over the last two 
decades contributing to confusion regarding frequency, 
prognosis and management of these entities (1). Despite 
these reporting inconsistencies, both entities have been 
considered adequate anatomic targets for thoracic 
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endovascular aortic repair (TEVAR) (2,3). Most PAUs 
are seen in the setting of diffuse and dense atherosclerotic 
disease, possibly including severe peripheral occlusive 
disease (4-6). These characteristics may preclude a suitable 
TEVAR due to disease of the access vessel and increased 
risk of neurologic complications due to the endovascular 
maneuvers in the aortic arch which often has a heavy 
burden of vulnerable atheroma (4,7).
The purpose of this study is to describe our experience, 
approach, and outcomes with aortic arch and vascular access 
challenges encountered during TEVAR performed for PAUs.
Methods
Patient cohort
This is a single center, observational cohort study of 
consecutive patients with PAU treated by TEVAR between 
October 2003 and February 2019. Due to the unpredictable 
natural history of thoracic PAUs, our institution adopted an 
aggressive approach in favor of operative repair (8,9). The 
following are indications for surgical repair for thoracic PAU:
 Asymptomatic lesion with diameter ≥30 mm and/or 
depth ≥10 mm (Figure 1A,B);
 Asymptomatic progressively enlarging “blister-like” 
lesion (Figure 2);
 Saccular pseudoaneurysm ≥50 mm or aortic lesion 
evolution into classic aortic dissection with detection 
of perfused true and false lumens;
 Symptomatic lesion (typical chest/back pain) in the 
presence of signs of impending rupture (crescent 
sign, pleural effusion) and/or persisting symptoms 
despite best medical treatment;
 “Shaggy aorta” with visceral/peripheral embolization 
syndrome;
 Free (hemothorax) or contained (periaortic hematoma) 
rupture (Figure 2C,D,E).
Patients diagnosed and treated for PAU located in the 
ascending aorta were not included in this analysis. The 
CONSORT diagram indicates all patients with thoracic 
PAU during the period of study, including the patient 
population from whom this series was derived (Figure 3). 
Informed consent for intervention was signed by each 
patient and approval for this specific study was obtained 
by the local Institutional Review Board, according to the 
National Policy Privacy Act regarding retrospective analysis 
of anonymized data. For this study, all cases were reviewed 
and debated by three senior authors [one vascular surgeon 
(GP) and two interventional radiologists (FF, FP)] with 
>20 years of experience in the diagnosis and treatment of 
thoracic aortic diseases. For the final analysis, the end of the 
study was March 1st, 2019.
Aortic lesion assessment and definitions
Each patient’s operative risk profile was defined after 
a multidisciplinary evaluation which included the 
Figure 1 Preoperative CTA with volume rendering 3D reconstruction (A) of a distal aortic arch PAU. Calcifications (dotted arrow) are 
typically present at the edges of the ulcer. Axial image (B) shows the measurements of the ulcer: diameter (Ø), depth (D), and length (L). 
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clinical visit, laboratory blood tests and biomarkers 
(leucocytes, procalcitonin, and C-reactive protein), and 
cardiorespiratory tests (10,11). Although a definitive 
imaging-based distinction has not been established by any 
radiologic/pathologic correlative study, we distinguished 
PAU from ULP. PAU is a focal lesion that ulcerates the 
intima and disrupts the internal elastic lamina of the aortic 
wall, has calcifications of the ulcer edges that are typical 
of atherosclerotic plaques, and could be accompanied by a 
hematoma localized around the lesion (Figures 1B,2B,C,D,E) 
(1,12). Ulcer measurements included maximal aortic 
diameter, depth, and length of intimal defect (Figure 1A) 
(9,13). The maximum aortic diameter and wall features 
were evaluated by visual inspection, comprising the largest 
external diameter and eventual wall hematoma thickness. 
The severity of the atheromatous disease was assessed 
by preoperative computed-tomography scans and scored 
using a modified scale which has been shown to correlate 
stroke risk with shaggy aorta defined by the presence of an 
irregular and protruding atheroma thickness >5 mm (14). 
Three categories of aortic arch shape were defined 
according to the classification of Ou et al. (15). The “gothic-
like” configuration was characterized by a steep angulation 
between the ascending and descending aorta with a 
short transverse portion of the aortic arch. The crenel 
configuration was characterized by a “rectangular-like” 
form with a normal length of the horizontal aorta and the 
Romanesque aortic arch has a smooth semicircular form. 
Patient co-morbidities, PAU morphologic characteristics, 
postoperative outcomes, and follow-up index (FUI) were 
Figure 2 Two cases of PAU of the distal aortic arch (A,B) and of the descending thoracic aorta (C,D,E,F). Axial images (A1-A3) show the 
enlargement evolution of a “blister-like” lesion over a 2-year period. Volume rendering 3D reconstructions show, preoperatively (B1), the 
location and the typical calcifications surrounding focally only the aorta affected by the PAU. Postoperatively (B2) the result of TEVAR after 
24 months follow-up with the complete exclusion of the lesion, and the good apposition of the SG at the inner curve in such a Romanesque 
aortic arch. Preoperative CTA of a contained rupture (C) of a descending PAU with the typical calcifications of the entire aorta (D). Volume 
rendering 3D reconstructions of the same case: preoperative (E) and postoperative (F) after 12 months of follow-up. PAU, penetrating aortic 
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defined according to recommended reporting standards 
documents (16-19). Favorable aortic remodeling was 
defined by the complete exclusion of the ULPs and 
diameter reduction ≥10 mm from the preoperative diameter 
in the absence of any stent-graft (SG) induced intimal 
defects (Figure 4). Major outcomes measures were early 
(<30 days) and late survival, freedom from aortic-related 
mortality (ARM), and a composite outcome of arch and/ or 
access-related issues.
Treatment protocol and follow-up
All operations were performed in the operating theatre 
using general anesthesia. For focal, saccular lesions, healthy 
landing zones of 15 mm from the affected zone were used 
in all cases (20). Oversizing of the endovascular grafts 
was 10% or less. Graft materials and manufacturers are 
reported in the Appendix (supplemental material). The 
protocol for spinal cord ischemia (SCI) prevention agreed 
with the position statement of the European Association for 
Cardio-Thoracic Surgery (EACTS) vascular domain (21). 
Post-deployment angioplasty was only used selectively to 
ensure SG-wall apposition. During follow-up, triple-phase 
computed tomography angiography (CTA) was performed 
at 1 and 12 months, and on an annual basis thereafter. 
Maximum aortic diameters were measured on preoperative 
and the most recent postoperative CTA.
Statistical analysis
Clinical data were prospectively recorded and tabulated 
in a Microsoft Excel (Microsoft Corp, Redmond, Wash) 
database. Statistical analysis was performed with SPSS 
(Version 25.0 IBM SPSS Inc. Chicago, IL, USA). 
Continuous variables were tested for normal distribution 
by the Kolmogorov-Smirnov test and compared between 
groups with unpaired Student’s t-test for normally 
distributed values, otherwise the Mann-Whitney U test was 
employed. For categorical variables, we used the Pearson’s 
χ2-test or Fisher exact tests as appropriate. Continuous 
variables were presented with mean ± standard deviation 
(SD) and interquartile (IQR) range, otherwise medians with 
Assessed for eligibility (n=263)
Penetrating aortic ulcers (n=51, 19.4%)
Cohort analysis (n=37, 14.1%)
Chronic asymptomatic, n=26
Acute symptomatic, n=11



























Figure 3 Consort diagram indicating all descending and thoracoabdominal aneurysm patients during the period of study, including the 
patient population from which this series was derived. DTA, descending thoracic aneurysm; TAAA, thoraco-abdominal aortic aneurysm; 
TBAD, type B aortic dissection; IMH, intramural hematoma; PAU, penetrating aortic ulcer.
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Figure 4 A case of “giant” PAU of the hiatus (A) with the typical calcification at the edge of the ulcer (A1) clearly visible at the preoperative 
volume rendering 3D reconstruction. Follow-up CTA at 36 months shows the complete shrinkage of the lesion after plug embolization 
of the celiac trunk (B, dotted arrow) and TEVAR with intentional overstenting of the celiac trunk and distal landing zone at the superior 
boarder of the superior mesenteric artery (B1). PAU, penetrating aortic ulcer; TEVAR, thoracic endovascular aortic repair.
range were applied. Categorical variables were presented 
using frequencies and percentages. A stepwise logistic 
regression model was developed to identify patients and 
procedural variables associated with arch/access issues. 
The model was built using variables that demonstrated 
a P value <0.20 in univariable analysis. The strength of 
the association of variables with arch/access issues was 
estimated by calculating the odds ratio (OR) and 95% 
confidence intervals (CI). The model was calibrated by the 
Hosmer-Lemeshow goodness-of-fit test, as well as residual 
diagnostics (deviance and df β); model discrimination was 
evaluated by using the area under the receiver operating 
characteristic (AUROC) curve. Kaplan-Meier curves, ± 
standard error (SE) and 95% CI, estimated the probability 
of survival or freedom from any adverse aortic events. All 




We treated 37 PAUs with TEVAR during the study period. 
At presentation, patients were symptomatic for thoracic 
pain (n=8, 21.6%), hoarseness (n=3, 8.1%), peripheral 
embolization syndrome (n=2, 5.4%), or hemoptysis (n=2, 
5.4%). Rupture with hemorrhagic shock was present in 
4 (10.8%) patients. Demographic data and risk factors 
are presented in Table 1. To summarize, patients who 
had arch and/or access issues had a history of previous 
cerebrovascular accidents (40% vs. 3.7%, OR: 8.23, 
P=0.014), more synchronous aortic lesions (70% vs. 22.2%, 
OR: 7.31, P=0.017), and showed a trend of smaller access 
vessel diameter (6.7±1.5 vs. 7.7±1.5 mm, P=0.081). There 
were no patients with known connective tissue disorders.
PAU morphology
Morphologic characteristics of PAUs and access vessels 
are reported in Table 2. Twenty-four (64.9%) PAUs 
presented as a saccular pseudoaneurysm, while a “blister-
like” morphology was present in 5 (13.5%). A “shaggy 
aorta” was seen in 3 (8.1%) patients. In 29 (78.4%) cases, 
the PAU was a single lesion in the descending thoracic 
aorta and in 8 (21.6%), we detected ≥ 2 lesions. In 3 (8.1%) 
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patients, there was also a PAU seen in the infrarenal aorta. 
Arch atheroma grade 3 or higher was present in 8 (21.6%) 
cases, and an associated local intramural hematoma was 
present in 14 (37.8%) cases. The aortic arch configuration 
was Romanesque in 28 (75.7%) patients, “Gothic-like” in 4 
(10.8%), and crenel in 2 (5.4%).
Data of operative repair
Femoral artery access was used for endovascular graft 
delivery in 34 (91.9%) cases. Mean aortic length coverage 
was 148±15 mm (range, 100–320; IQR, 100–150). The 
origin of the left subclavian artery was completely covered 
and revascularized during the same operation in 6 (16.2%) 
patients. Additional vascular procedures were performed 
in 15 (40.5%) patients with 5 involving the access vessel. 
Operative details of all SG interventions are reported in 
Table 3.
Early outcomes
Primary technical success was 94.6% (n=35). In 1 (2.7%) 
case, a low-flow proximal type 1 endoleak was sealed with 
an extension cuff, and a retrograde acute type A dissection 
(RATAD) required emergent open conversion for repair. 
Eleven (29.7%) patients were admitted to the intensive care 
unit (ICU) following TEVAR and all but 2 were extubated 
in the immediate postoperative period. Most (n=9) of these 
patients remained in ICU <24 hours after the intervention, 
Table 1 Demographic data, co-morbidities, and risk factors of the 
cohort of 37 PAUs treated with TEVAR
Variable n (%)
Demographic data
M:F (ratio) 24 (64.9):13 (35.1)





Obesity (BMI >30) 14 (37.8)




Ischemic heart disease 10 (27.0)
Chronic atrial fibrillation 9 (24.3)
Diabetes 6 (16.2)
Previous cerebrovascular events 5 (13.5)
Renal insufficiency (GFR <30 mL/min) 5 (13.5)
Previous AAA surgery 3 (8.1)
Risk profile
Free rupture 4 (10.8)
EuroSCORE* 27±18.5  
(IQR, 14.5–32.3)
*, http://euroscore.org/calc.html. TEVAR, thoracic endovascular 
aortic repair; PAU, penetrating aortic ulcer; n, number; M, male; F, 
female; IQR, interquartile range; SD, standard deviation; CODP, 
chronic obstructive pulmonary disease; BMI, body mass index; 
AAA, abdominal aortic aneurysm; GFR, glomerular filtration rate.
Table 2 Morphologic characteristics of the 37 PAUs
Variable n (%)
Aortic segment
Transverse arch 3 (8.1)
Distal arch 13 (35.1)
Descending 19 (51.4)
Hiatus 2 (5.4)




Distance from CT 12±7.5 [5–19]
Access vessel




Extensive but limited 9 (24.3)
Extensive and severe 10 (27.0)
PAU, penetrating aortic ulcer; n, number; IQR, interquartile 
range; SD, standard deviation; CT, celiac trunk.
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while 2 required prolonged (>10 days) ICU stay. In-hospital 
mortality was 8.1% (n=3). There was no statistically 
significant difference in mortality between patients who 
receive either urgent or elective treatment [n=2 (18.2%) vs. 
n=1 (3.8%), P=0.144]. The causes of death were RATAD 
(n=2) and small bowel infarction (n=1). Table 4 presents 
postoperative complications. There was no incidence of 
fatal or disabling stroke. The median length of stay was 
6 days (range, 1–135; IQR, 4–7).
Arch and access-related issues
Overall, we observed 10 (27.0%) arch and/or access-
related issues. Of the 4 (10.8%) arch issues, 2 transient 
ischemic attacks resolved spontaneously without any 
Table 3 Technical details and intraoperative data
Variable n (% or IQR)
Stent-graft
Free-flow 19 (51.3)
Diameter (mm ± SD) 34±4 (IQR, 34–37)
1 sg 31 (83.8)
2 sgs 6 (16.2)
Operative data
General anesthesia 37 (100.0)
Femoral access 34 (91.9)
LSA coverage 6 (16.2)
Aortic coverage (mm ± SD) 148±5 (IQR, 100–150)
<20 30 (81.1)
≥20 7 (18.9)
Intervention (min ± SD) 121±105 (IQR, 60–120)
Blood loss (median, mL) 50 (IQR, 50–200)
Contrast (min ± SD) 91±40 (IQR, 60–120)
Adjunctive procedures
CS bypass + LSA plug 5 (13.5)
EVAR 3 (8.1)
Femoral patch 2 (5.4)
LSA “chimney” 1 (2.7)
SAT debranching 1 (2.7)
Visceral debranching 1 (2.7)
CT plug 1 (2.7)
Renal artery stenting 1 (2.7)
Iliac artery PTA 1 (2.7)
Pseudoaneurysmectomy 1 (2.7)
n, number; SG, stent-graft; mm, millimeters; cm, centimeters; 
min, minutes; mL, milliliters; IQR, interquartile range; SD, 
standard deviation; CS, carotid-to-subclavian; LSA, left 
subclavian artery; EVAR, endovascular abdominal aortic repair; 
PTA, percutaneous transluminal angioplasty.
Table 4 Postoperative complications, grading classification, and 
treatment of patients treated with TEVAR




SVS grade 1 SCI 1 (2.7) Rehabilitation Recover
Pulmonary 
embolism
1 (2.7) LMWH Uneventful
Post-implant 
syndrome
1 (2.7) Conservative Recover
Atrial fibrillation 1 (2.7) Amiodarone Recover
Moderate
Acute kidney injury 3 (8.1) Hydratation Recover
TIA 2 (5.4) Rehabilitation Recover
Wound hematoma 1 (2.7) Surgical 
exploration
Recover
Wound infection 1 (2.7) Surgical 
debridement
Recover




RATAD 2 (5.4) Open repair Dead
Pyothorax 1 (2.7) VAT evacuation Recover
Small bowel 
infarction
1 (2.7) Resection Dead
Pneumonia 1 (2.7) Antibiotic 
therapy
Recover
TEVAR, thoracic endovascular aortic repair; n, number; LMWH, 
low molecular weight heparin; SCI, spinal cord ischemia; TIA, 
transient ischemic attack; SVS, Society for Vascular Surgery; 
RATAD, retrograde acute type A aortic dissection; VAT, video-
assisted thoracic evacuation.
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residual deficit or disability, while 2 RATADs required 
emergent open conversion (immediate postoperative, 
n=1; later on day 3rd postoperatively, n=1). Both patients 
died on postoperative days 1 and 3. Access issues occurred 
in 6 (16.2%) patients. In 4 cases, the small caliber of the 
femoral vessels necessitated a planned conduit on the 
common iliac artery (n=3) or iliac angioplasty (n=1) to 
introduce the SG. In addition, 2 (5.4%) patients developed 
access complications following TEVAR which required 
surgical reconstruction [femoral patch angioplasty (n=2) 
and femoral pseudoaneurysmectomy (n=1)]. The mortality 
rate in patients with arch/access issues was 5.4% (n=2). 
Diabetes, a previous history of cerebrovascular accident, 
severely atheromatous arch, and associated aneurysmal 
abdominal aortic disease was found to be associated with 
access and arch issues. However, multivariable analysis 
demonstrated that a previous history of cerebrovascular 
accidents (OR: 2.72; 95% CI: 1.198–4.321, P=0.031) was 
significantly associated with arch/access vessel issues. The 
AUROC for this model was 0.681, suggesting the ability 
to identify individuals who will have arch/access issue. The 
Hosmer-Lemeshow goodness-of-fit test was not significant 
[χ2 (6 df) =4.54; P=0.604], indicating that there was not 
statistically significant departure from a perfect fit.
Late outcomes
Median follow-up was 24 (range, 1–156; IQR, 3–52) 
months: FUI was 0.9±0.1. During the follow-up period, 17 
(50%) patients died: causes of death reported in Table 5. 
Overall, estimated survival was 87.1% (SE: 0.6; 95% 
CI: 71.2–84.9%) at 1 year and 63.3% (SE: 0.9; 95% CI: 
44.1–79%) at 4 years (Figure 5A). Twenty-four (70.6%) 
patients had an available CTA at 12 months, 14 (41.2%) at 
36 months, and 9 (26.5%) had follow-up CTA ≥ 60 months. 
Favorable aortic remodeling was observed in 30 (88.2%) 
cases. No additional arch/access-related issues developed 
during the follow-up. TEVAR-related adverse events were 
observed in 4 (11.4%) patients. There were 2 fistulas (aorto-
bronchial and aorto-esophageal) that led to sudden death 
at the time of the re-admission, a proximal type 1 endoleak 
in a patient who declined endovascular re-intervention 
(n=1), and a SG-induced intimal defect that is still under 
surveillance without any aortic-related adverse event (n=1). 
The estimated freedom-from reintervention rate was 88.9% 
(SE: 0.5; 95% CI: 74.8–95.6%) at 1 year and 84.2% (SE: 
0.7; 95% CI: 67.3–93.2%) at 4 years (Figure 5B).
Discussion
Thoracic PAUs have been defined as an ideal surgical 
indication for TEVAR. The lesions tend to be focal and 
develop in the relatively straight segment of the descending 
thoracic aorta in 59–100% of the cases. A recent consensus 
statement recommends TEVAR to be the first line option 
in the treatment of PAUs (1,4). However, consistent with 
other aortic diseases, TEVAR may be challenging if there 
are anatomical constraints for current SG technology.
Typically, patients with PAUs have severely calcified, 
small diameter iliac and -femoral vessels and may have 
high grade atheroma in the aortic arch which may preclude 
repair or increase the risk during TEVAR (22). Therefore, 
careful evaluation of the most appropriate and safest access 
for SG insertion is of utmost importance. The surgeon 
needs to be familiar with alternative access options such 
as the retroperitoneal exposure of iliac arteries (23,24). 
Interestingly, peripheral arterial obstructive disease 
involving iliac and/or femoral vessels has only been reported 
as a risk factor by a few authors (Table 6). A comprehensive 
Table 5 Causes of death during the follow-up
Cause of death n
Cardiovascular
Acute myocardial infarction 4













Traumatic brain hemorrhage 1
n, number.
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literature review revealed that an iliac conduit for stent 
graft delivery was required in up to 46% of the cases 
(5,11,25-32). Furthermore, small caliber or severely 
diseased iliac and femoral arteries may be prone to 
complications such as disruption, thrombosis, dissection 
and false aneurysm (7,22,23,33,34). In our experience, a 
vascular access issue was encountered in 16.2% of the cases. 
This rate includes both common iliac artery conduits and 
unplanned vascular reconstruction to repair iatrogenic iliac 
or femoral injuries. These two different situations highlight 
the severity of the atherosclerotic burden that affects access 
vessels in these patients.
Our data yield additional observations. First, while the 
overall rate of access-related issues is less than previously 
reported, our 5.4% rate of access complication is in line 
with the 0–5.2% range observed in our literature review 
(5,11,25-32). Second, our infrequent use of conduits may 
reflect meticulous preoperative planning or the lower 
profile of newer endovascular devices. Regardless, access 
complications remain a concern (24). Our complication 
rate is similar to clinical series from the past decade when 
SG devices were of larger profile and had bulky introducer 
sheaths. Indeed, these data emphasize that the access 
artery quality may be compromised by the severity of the 
atherosclerotic disease especially in patients with PAUs (31).
From an anatomical point of view, the extent of the 
involved aorta is much less in PAU than aneurysmal 
disease and the lesion itself is also often short in length 
(6,11). These anatomical features may be, for example, 
favorable by limiting an important complication such 
as SCI occurrence but do impact on other threatening 
complications especially when located in the aortic arch 
(2,7,28). For example, the risk of stroke in patients with 
PAUs has been reported to be similar for TEVAR and open 
surgery (4% vs. 7%, respectively) (1). In our series, a history 
of previous cerebrovascular events, not correlated to carotid 
artery disease, independently predicted the occurrence of 
an arch issue. This data finds support in previous experience 
that showed TEVAR in patients with a history of stroke 
had the highest perioperative stroke rate (14). These results 
show how the underlying burden of atheromatous disease, 
that is common in this population, makes the aortic arch 
vulnerable to complications during TEVAR (35).
Another important aortic arch issue in our experience 
was the occurrence of RATAD. In our complete TEVAR 
experience, this complication has only been seen in the 
PAU cohort. Our observation is somewhat unexpected as 
recent large registries have reported a 0–2% prevalence of 
RATAD after TEVAR for PAU (36,37). In our opinion, our 
two instances should not be ascribed only to a potentially 
fragile aorta. We believe that one RATAD was triggered by 
ballooning of the SG at its proximal edge, while the other 
event occurred in a patient whose aorta was potentially suitable 
for off-pump debranching (ascending aorta of 40 mm).
Patients with PAUs have not been considered ideal 
candidates for conventional open surgical repair due to 
the systemic distribution of atherosclerotic disease (1,4,6). 
We believe this observation hold for patients undergoing 
TEVAR (3,9,22,26,28,32,34). First, while TEVAR may 
have decreased in-hospital mortality by 39% compared 
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Time from intervention, (months)
No. at risk 23 18 13 10
Survival (%) 87.1 76.2 63.3 63.3
S.E. 0.6 0.8 0.9 0.9
95% CI 71.2–84.9 58.3–88 44.1–79 44.1–79
No. at risk 23 18 13 10
Survival (%) 88.9 84.2 84.2 84.2
S.E. 0.5 0.7 0.7 0.7
95% CI 74.8–95.6 67.3–93.2 67.3–93.2 67.3–93.2
A B
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to mortality predicted by the operative risk, our 8.1% 
mortality rate for PAU is still too high (1,16). Though our 
mortality rate is similar to other series reporting 0–12%, 
this relatively high mortality rate emphasizes the fact 
that patients with PAU are a high-risk group despite the 
minimally invasive nature of TEVAR (5,11,25-32). Second, 
mortality rate remained high during the follow-up period 
mainly due to cardiovascular events. ARM during follow-
up did not occur in this cohort, but the 63% overall survival 
at 4 years is consistent with other series attesting that these 
patients are high risk and fragile (11,25,28,31,32).
The present study has obvious limitations. First, it is a 
retrospective study. Second, it has sampling bias in that patients 
undergoing open repair were not included for comparison. 
Last, the small number of patients and events makes results 
of multivariate analysis not generalizable. However, data 
on PAUs are variable and confounded by heterogeneity 
of lesions and paucity of long-term follow-up (9). Despite 
these limitations, our inclusion criteria create a relatively 
homogeneous cohort and patient follow-up was excellent. Our 
outcomes adhered systematically to the proßposed guidelines 
and compare well with other studies (17,18).
In conclusion, our experience reaffirms that access vessel 
and aortic arch issues remain a major challenge in the 
performance of TEVAR for PAUs. The cumulative 27% rate 
of access/arch issues in our patients is lower than previously 
reported and may be explained by meticulous evaluation and 
careful surgical planning as well as device advancements for 
both access routes and arch anatomy. Patients with PAUs 
remain a cohort at high risk for TEVAR. Both in-hospital 
and mid-term mortality rates are high, even in the TEVAR 
era, a fact that underscores the impact of the high burden of 
atherosclerotic disease which characterizes these patients.
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